Long-term Persistence of Azithromycin: Risk or Benefit?

Infections in Medicine

Volumn 15, Issue SUPPL. A, 1998, Pages 10-14

  Crokaert, Françoise ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Azalides; Azithromycin; Macrolides; Pharmacokinetics

Indexed keywords

AZITHROMYCIN; MACROLIDE;

ADULT; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; ELECTROCHEMICAL DETECTION; GRAM NEGATIVE BACTERIUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RISK BENEFIT ANALYSIS; SKIN INFECTION;

EID: 0031971559     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Amsden GW: Erythromycin, clarithromycin, and azithromycin: Are the differences real? Clin Ther 18(1)56-72,1996.
2. Zuckerman JM, Kaye KM: The newer macrolides. Azithromycin and clarithromycin. Infect Dis Clin North Am 9(3):731-745,1995.
3. Charles L, Segreti J: Choosing the right macrolide antibiotic: A guide to selection. Drugs 53(3):349-357,1997.
4. Baquero F, Negri MC, Morosini MI, et al: The antibiotic selective process: Concentrationspecific amplification of low-level resistant populations. Ciba Found Symp 207:93-111, 1997.
5. Gibaldi M, PerrierD (eds): Pharmacokinetics, ed 2. New York, Marcel Dekker, 1982.
6. Takahashi K, Duchateau V, Husson M, Bourguignon AM, Crokaert F: A human model of local abscess using skin chambers: Penetration of azithromycin (AZ) and ciprofloxacin (C1P). Abstracts from the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, La., September 15-18,1996. Abstract A81.
7. Lalak NY, Morris DL: Azithromycin clinical pharmacokinetics. Clin Pharmacokinet 25:370-374,1993.
8. Luke DR, Foulds G, Cohen SF, et al: Safety, toleration, and pharmacokinetics of intravenous azithromycin. Antimicrob Agents '' Chemother40(11):2577-2581.
9. Foulds G, Shepard RM, Johnson RB: The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 25(supplA):S73-S82,1990.
10. Schentag JJ, Forrest A, Nix DE, et al: Relationship between serum, intracellular, and infection site concentrations of macrolides and azalide antibiotics-A theoretical exploration of the concept of white blood cell drug delivery to infection sites. Antiinfect Drugs Chemother 14:137-146,1996.
11. Foulds G, Johnson RB: Selection of dose regimens of azithromycin. J Antimicrob Chemother 31(suppl E):S39-S50,1993.
12. Mallory SB: Azithromycin compared with cephalexin in the treatment of skin and skin structure infections. Am J Med 25(suppl A):S36-S41,1991.